Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination With Osimertinib in Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT03455829 is registered in ClinicalTrials.gov with G1 Therapeutics, Inc. as lead sponsor.

NCT NCT03455829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03455829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination With Osimertinib in Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
G1 Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
March 29, 2018
Completion date
February 14, 2022
Enrollment
30 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, lung cancer, non-small cell lung cancer